🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In JAMA Cardiology editorial on Jenica Upshaw et al, analysis of SEER data, Ana Barac, MD, PhD, FACC, FAHA discusses risks/benefits of anthracyclines & cardioprotective strategies in patients with DLBCL & preexistent HF jamanetwork.com/journals/jamac… jamanetwork.com/journals/jamac…

#Afib #ablation is equally effective & safe in patients with history of #Cancer #chemo #radiation as compared to those without cancer Outcomes are encouraging in selected pts Cancer shouldn't be a deterrent for appropriate #CVD care in #survivorship #cardiooncology #EPeeps

One week away! Join inaugural joint sessions w ASCO & ASH on #breastcancer #cellulartherapies #survivorship. Look forward to learning from amazing faculty Alicia Morgans, MD, MPH Mamas A. Mamas Pradeep Natarajan Lauren A. Baldassarre, MD, FACC, FSCCT, FSCMR Daniel Addison, MD Christina Dieli-Conwright, PhD, MPH

Evidence of a cardiac wasting-associated cardiomyopathy in cancer where low LV mass was associated with poor functional status and increased all-cause mortality. pubmed.ncbi.nlm.nih.gov/37076211/

From our #NutritionHF team🍎: Cachexia independently associated with ­mortality during #LVAD support, whereas early post-LVAD weight gain ≥5% is associated with ↑ subsequent survival ahajournals.org/doi/epdf/10.11… Tufts Medical Center Research Joronia Chery, MD Jenica Upshaw JAHA

Breaking🔥 STEP-HFpEF-DM 🔥 Semaglutide (vs placebo) leads to more weight loss, improved health status (KCCQ-CSS), increased walking distance, improved glycemic control, reduced inflammation (CRP), reduced natriuretic peptides, reduced HF hospitalizations, with favorable safety

Presented today at #ACC24: In the DanGer Shock trial involving patients with STEMI and cardiogenic shock, mortality at 6 months was lower with mechanical circulatory support with a microaxial flow pump than with standard care alone. Full trial results: nej.md/3xyXU3t

#ACC2024 LBT SMART trial ➡️Self- vs balloon-expandable TAVR in small annuli 🌎716 all-comer AS pts, 13 countries, 87% women !! 🎯SEV (78% EvolutPRO+)non-inferior 1y clinical outcome, superior valve performance (lower dysfunction/gradient/PPM, higher EOA/DVI) NEJM great for 👩

#cardioonc lbct today at #ACC24 Proact trial. Negative again. Enalapril does not impact cardiac injury or cardiac function in patients treated with anthracyclines. Time to look for beyond this class? #jacccardioonc

Check out this commentary led by Jenica Upshaw “Dexrazoxane to Prevent Cardiotoxicity in Adults Treated with Anthracyclines” ➡️ Controversies in Cardio-Oncology sciencedirect.com/science/articl… Kathryn Ruddy Tufts Medical Center OncoAlert #cardioOnc

Older patients with #Hodgkin #lymphoma have high burden of #HF, high 1 year mortality and low of anthracyclines and cardioprotective meds. Need improved #cardioonc strategies in this population. Check out the latest #JACCCardioOnc issue on anthracyclines jacc.org/toc/cardio-onc…

Thoracic #RadOncs - check out our new paper in JACC CardioOnc! Simple heart features on planning CT were associated with risk of specific cardiac events after RT for NSCLC (n=478) Is it time we got Cardiology input on some of our patients? Thread (/14)...

🚨 St Francis Heart Center, NY #CardioOnc Journal Club 📖 with OPCI . St. Francis Hospital & Heart Center Catholic Health Great hosting Jenica Upshaw (Tufts University) to discuss Hodgkin lymphoma treatment 🩺 outcomes among older heart failure patients. Watch episode: opci.live/opci-lives/hod…

Excited to announce our latest #CardioOncology research: "HFA-ICOS score predicts anthracycline-related CV toxicity and all-cause mortality". Congratulations to the CardioTox team! academic.oup.com/eurheartj/adva… EHJ Editor-in-Chief CardioQuironMadrid International Cardio-Oncology Society Borja Rivero Santana Jesús Saldaña García Cardiología La Paz

What a tremendous honor and privilege to cochair this HFSA scientific statement on cardio-oncology and HF, published online today Journal of Cardiac Failure with the great, and unparalleled Ana Barac, MD, PhD, FACC, FAHA

Long awaited IELSG37 Trial Results: Patients with mediastinal large B-cell lymphoma who achieve Deauville scores of 1-3 on PET after immunochemotherapy have excellent outcomes and do not require consolidative radiation therapy. Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

CLEAR results are in Colchicine is out (at least for #AMI) #AHA24 NEJM AMI tx with colchicine did not ⤵️ incidence of the composite primary outcome (☠️from CV causes, recurrent Mi, stroke, unplanned revascularization) 📎 rb.gy/8pnnhd

Exciting investment in research to improve CV health in women. Heart disease is the leading cause of death in women. Much to do to improve women’s CV health. Let’s do it!#AHA2024

Everything you need to know about arrhythmias in cancer patients from Mike Fradley, MD . Great #cardioonc session at #AHA24. Much research to be done to define best strategies in cancer patients

Congrats to the SARAH study team and on important #cardioonc RCT of sacubitril-valsartan in anthracycline treated patients with +Tn LBCT at #AHA24 Need larger multicenter trials to confirm and understand outcomes if/when entresto discontinued. Great discussion by Dr. Bonnie Ky!